S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
LON:GSK

GSK (GSK) Price Target & Analyst Ratings

GBX 1,367.60
+20.00 (+1.48%)
(As of 06/2/2023 ET)
Compare
Today's Range
1,336.58
1,369.60
50-Day Range
1,346.40
1,523
52-Week Range
1,280.92
2,280.50
Volume
4.63 million shs
Average Volume
7.83 million shs
Market Capitalization
£55.39 billion
P/E Ratio
1,254.68
Dividend Yield
4.09%
Price Target
GBX 1,573.33

GSK Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 8 Analyst Ratings

Consensus Analyst Price Target

GBX 1,573.33
High PredictionGBX 2,000
Average PredictionGBX 1,573.33
Low PredictionGBX 1,245
TypeCurrent
6/2/22 to 6/2/23
1 Month Ago
5/3/22 to 5/3/23
3 Months Ago
3/4/22 to 3/4/23
1 Year Ago
6/2/21 to 6/2/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 1,573.33GBX 1,573.33GBX 1,551.11GBX 1,758.08
Get GSK Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.


GSK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GSK Stock vs. The Competition

TypeGSKMedical Companies
Consensus Rating Score
2.38
2.66
Consensus RatingHoldBuy
News Sentiment RatingNeutral News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/30/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral
5/30/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 1,700+22.81%
5/15/2023Shore Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
5/9/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUnderweight
4/27/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingEqual WeightGBX 1,450+0.86%
4/19/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 1,730+17.62%
3/6/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Keyur Parekh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetGBX 2,000+38.68%
2/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Dominic Lunn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutralGBX 1,510+6.16%
2/1/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Leuchten
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetGBX 1,245-13.73%
2/1/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Peter Welford
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set TargetGBX 1,575+9.14%
(Data available from 6/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GSK Price Target - Frequently Asked Questions

What is GSK's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for GSK stock is Hold based on the current 1 sell rating, 3 hold ratings and 4 buy ratings for GSK. The average twelve-month price prediction for GSK is GBX 1,573.33 with a high price target of GBX 2,000 and a low price target of GBX 1,245. Learn more on GSK's analyst rating history.

Do Wall Street analysts like GSK more than its competitors?

Analysts like GSK less than other Medical companies. The consensus rating for GSK is Hold while the average consensus rating for medical companies is Buy. Learn more on how GSK compares to other companies.

Is GSK being upgraded by Wall Street analysts?

Over the previous 90 days, GSK's stock had 1 upgrade by analysts.

Does GSK's stock price have much upside?

According to analysts, GSK's stock has a predicted upside of 8.33% based on their 12-month price targets.

What analysts cover GSK?

Stock Ratings Reports and Tools

This page (LON:GSK) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -